- Home
- BGNE vs ZTO Comparison
BGNE vs ZTO Comparison
Compare BGNE & ZTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BGNE
- ZTO
- Stock Information
- Founded
- BGNE 2010
- ZTO 2002
- Country
- BGNE Cayman Islands
- ZTO China
- Employees
- BGNE N/A
- ZTO N/A
- Industry
- BGNE Biotechnology: Pharmaceutical Preparations
- ZTO Advertising
- Sector
- BGNE Health Care
- ZTO Consumer Discretionary
- Exchange
- BGNE Nasdaq
- ZTO Nasdaq
- Market Cap
- BGNE 21.0B
- ZTO 18.5B
- IPO Year
- BGNE 2016
- ZTO 2016
- Fundamental
- Price
- BGNE $189.23
- ZTO $21.07
- Analyst Decision
- BGNE Buy
- ZTO Strong Buy
- Analyst Count
- BGNE 7
- ZTO 4
- Target Price
- BGNE $247.07
- ZTO $27.03
- AVG Volume (30 Days)
- BGNE 281.8K
- ZTO 2.2M
- Earning Date
- BGNE 11-12-2024
- ZTO 11-19-2024
- Dividend Yield
- BGNE N/A
- ZTO 4.60%
- EPS Growth
- BGNE N/A
- ZTO 3.16
- EPS
- BGNE N/A
- ZTO 1.43
- Revenue
- BGNE $3,351,304,621.00
- ZTO $5,556,884,220.00
- Revenue This Year
- BGNE $969.39
- ZTO $15.76
- Revenue Next Year
- BGNE $24.79
- ZTO $11.67
- P/E Ratio
- BGNE N/A
- ZTO $14.72
- Revenue Growth
- BGNE 50.22
- ZTO 7.57
- 52 Week Low
- BGNE $126.97
- ZTO $15.90
- 52 Week High
- BGNE $248.16
- ZTO $27.50
- Technical
- Relative Strength Index (RSI)
- BGNE 31.72
- ZTO 31.69
- Support Level
- BGNE $189.60
- ZTO $20.47
- Resistance Level
- BGNE $209.29
- ZTO $21.39
- Average True Range (ATR)
- BGNE 6.42
- ZTO 0.54
- MACD
- BGNE -2.10
- ZTO -0.28
- Stochastic Oscillator
- BGNE 9.19
- ZTO 16.35
About BGNE BeiGene Ltd.
BeiGene Ltd is a global oncology company that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. BeiGene's key cancer treatments are BRUKINSA (zanubrutinib), Bruton's tyrosine kinase (BTK) inhibitor, and TEVIMBRA (tislelizumab), an anti-PD-1 antibody. In addition, it has a diverse pipeline of novel therapeutics focusing on a range of malignancies, including AML, MDS, multiple myeloma, lung, gastrointestinal, breast, and gynecologic cancers. The Company operates in one segment: pharmaceutical products and is primarily located in the U.S. and the PRC. Key revenue is generated from the U.S.
About ZTO ZTO Express (Cayman) Inc. each representing one ordinary share.
ZTO Express is China's largest express delivery company by parcel volume, with a volume share of 22.1% in 2022. It operates a network partner model where it provides line-haul transportation and sorting services, while its local network partners provide first-mile pickup and last-mile delivery services under the ZTO brand name. Headquartered in Shanghai, the company was founded in 2002 by Meisong Lai, who remains chair, CEO, and its major shareholder with 77% voting rights as of June 30, 2023. ZTO's strategic shareholder is leading China e-commerce company Alibaba Group with around an 11.7% interest.